Outlook for the next 5 years in drug innovation

被引：32

作者：

Berggren, Roy ^{[2
]}

Moller, Martin ^{[1
]}

Moss, Rachel ^{[3
]}

Poda, Pawel ^{[4
]}

Smietana, Katarzyna ^{[4
]}

机构：

[1] McKinsey & Co Inc, DK-1061 Copenhagen K, Denmark

[2] McKinsey & Co Inc, New York, NY 10022 USA

[3] McKinsey & Co Inc, London SW1Y 4UH, England

[4] McKinsey & Co Inc, PL-50365 Wroclaw, Poland

来源：

NATURE REVIEWS DRUG DISCOVERY | 2012年 / 11卷 / 06期

关键词：

RESEARCH-AND-DEVELOPMENT;

D O I：

10.1038/nrd3744

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Analysis of industry pipeline data and revenue forecasts highlights several trends in the anticipated output of new drugs and the therapeutic area focus over the next 5 years, including a growth in the average number of new drug approvals annually.

引用

页码：435 / 436

页数：2